Latest Content

The FDA communicated that the phase 2 IDeate-Lung01 results were not sufficient for an accelerated approval of I-DXd in small cell lung cancer.

Broad oncology bundles falter; experts push smaller surgery/radiation episodes, better navigation, and AI analytics to improve value-based care.

Elinzanetant, already approved for menopause-related VMS, is being considered to address hot flashes associated with adjuvant breast cancer endocrine therapy.

The phase 2 ALISCA-Lung2 trial (PUMA-ALI-4202) is exploring alisertib plus paclitaxel in small cell lung cancer after immunotherapy and chemotherapy.

In the phase 3 EXCALIBER-RRMM trial, iberdomide plus daratumumab and dexamethasone doubled MRD-negative complete response rates over standard therapy in relapsed myeloma.

Closing sessions at IMS 2026 featured MRD-guided treatment strategies, real-world CAR T-cell data, and mixed results on cilta-cel neurotoxicity prevention in myeloma.

Durvalumab plus enfortumab vedotin improved EFS and OS in MIBC and will be considered for FDA approval in the fourth quarter of 2026.

Etentamig significantly improved response and survival over standard therapy in the phase 3 CERVINO trial, headlining day 3 of IMS 2026 myeloma coverage.

In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.

FDA approves belzutifan plus lenvatinib for advanced clear cell RCC after PD-1/PD-L1 therapy, based on PFS and response rate benefit vs cabozantinib.

Advisory panel backs Galleri blood test for adults 50+, citing strong specificity, mixed sensitivity, and follow-up impacts as FDA weighs approval.

Half of patients who stopped MRD-guided maintenance in GEM2014MAIN remained progression-free at 7 years, as IMS 2026 also featured DREAMM-9, MIDAS, and novel bispecific data.

LRRC15-targeting ADC SOT106 gains FDA fast track and orphan status for sarcomas, showing preclinical promise as it heads into a first-in-human trial.

The oral FGFR2 inhibitor lirafugratinib is now FDA approved for the second-line treatment of cholangiocarcinoma harboring FGFR2 alterations.

A new IMS/IMWG consensus definition requires 5 years of treatment-free, MRD-negative remission before multiple myeloma can be called cured.

Dr Raj Singh previews key ASTRO 2026 data, from FMISO PET-guided de-escalation in HPV-positive head and neck cancer to SRS vs whole brain radiotherapy trials in brain metastases.

New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML gaps, and inequities in access.

Mezigdomide plus elranatamab yielded a 100% ORR in MELT-MM, as other IMS 2026 abstracts covered cevostamab, anito-cel vs cilta-cel, and linvoseltamab in HR-SMM.

New 177Lu-dotatate radioligand therapy expands options for SSTR+ GEP-NETs, backed by NETTER-1 efficacy and key safety guidance.

For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.

The FDA has recommended conducting a new trial showing an OS benefit with tovecimig in biliary cancer before submitting a BLA.

NCCN guidelines indicate rusfertide for patients who are intolerant to phlebotomy or who receive frequent phlebotomy, regardless of risk status.

Community oncology practices rapidly adopt bispecific therapy, but reimbursement gaps, intensive monitoring demands, and limited hospital coordination hinder safe, scalable in-office programs.

Preview the 2026 International Myeloma Society meeting: the IMS/IMWG cure consensus, plenary session phase 3 trials, and new bispecific/CAR T myeloma findings.

During a roundtable event, Amit R. Mehta, MD, and participants discussed treatment selection for a patient with immune thrombocytopenia at risk of thrombotic events.

The FDA designation is for LYT-200 plus a hypomethylating agent for relapsed/refractory high-risk myelodysplastic syndromes.

Real-world ESAS data show higher symptom burden after cancer diagnosis shifts spending from treatment to ER, home and mental health care.

Jeff Sharman, MD, explores how targeted therapies have transformed CLL treatment and what emerging approaches could shape the future of care.

Updated TRUST-I and TRUST-II data show durable taletrectinib responses in ROS1+ NSCLC regardless of prior chemotherapy or fusion partner.

David DiBardino, MD, explains how intratumoral radioenhancer therapy works, why standardization remains a challenge, and what early CONVERGE study data suggest for locally advanced NSCLC.

Oncologists weigh second-line options after IO/TKI failure in metastatic ccRCC, highlighting tolerability, mechanism shifts, and belzutifan’s broader role.